9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Condition Mesothelioma Estimated Enrollment: 8 Age Group: 19 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: F090917002 (UAB 0901)|UAB 0901 Study First Received: September 15, 2010 Last Updated: May 20, 2016 Estimated Primary Completion Date: April 2015 Primary Outcome Measures: Evaluation of the tumor response rate following zoledronic acid|Evaluation of the duration of tumor response Sponsors and Collaborators: University of Alabama at Birmingham|Novartis Pharmaceuticals Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01204203...

Continue reading

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Condition Cancer Estimated Enrollment: 22 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2009/337 Study First Received: October 15, 2009 Last Updated: February 7, 2017 Estimated Primary Completion Date: September 2015 Primary Outcome Measures: Progression fee survival rate|Response rate according to modified RECIST criteria|Toxicity (CTCAE version 4)|Overall survival Sponsors and Collaborators: University Hospital, Ghent|Merck Sharp & Dohme Corp. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00996567...

Continue reading

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Condition Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma Estimated Enrollment: 34 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2009-00656|CDR0000539269|N0623|U10CA025224 Study First Received: April 11, 2007 Last Updated: January 28, 2015 Estimated Primary Completion Date: April 2009 Primary Outcome Measures: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)|Overall Survival|Progression-free Survival Assessed by RECIST|Determine the Clinical Toxicities of This Drug in This Participant Population.|Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.|Overall Response...

Continue reading

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Condition Malignant Pleural Mesothelioma|Solid Tumors Estimated Enrollment: 71 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CBP08-01 Study First Received: June 16, 2008 Last Updated: December 19, 2012 Estimated Primary Completion Date: July 2012 Primary Outcome Measures: Ph I: To determine the MTD of CBP501 + pemetrexed + cisplatin in patients with advanced solid tumors. Ph II: To evaluate the efficacy and safety profile of CBP501 + pemetrexed + cisplatin in patients with malignant pleural mesothelioma|Ph I: To determine the recommended CBP501 dose for exploration in the phase II part|Ph I:...

Continue reading

Isolated Thoracic Perfusion (ITP-F) for MPM

Condition Mesothelioma Estimated Enrollment: 23 Age Group: 18 Years to 80 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case Control|Time Perspective: Prospective Study ID Numbers: 0001 Study First Received: May 26, 2015 Last Updated: June 9, 2015 Estimated Primary Completion Date: January 2015 Primary Outcome Measures: Survival|Toxicity Sponsors and Collaborators: Medias Klinikum for Surgical Oncology Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02467426...

Continue reading

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Condition Mesothelioma Estimated Enrollment: 448 Age Group: 18 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: IFCT-GFPC-0701 Study First Received: March 29, 2008 Last Updated: September 1, 2016 Estimated Primary Completion Date: January 2015 Primary Outcome Measures: % of patients with controled disease (responder and stable patients) at 6 months|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 Sponsors and Collaborators: Intergroupe Francophone de Cancerologie Thoracique|University Hospital, Caen|Groupe Francais De Pneumo-Cancerologie Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00651456...

Continue reading

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 45 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: ELCWP-01062 Study First Received: March 5, 2008 Last Updated: February 11, 2015 Estimated Primary Completion Date: March 2009 Primary Outcome Measures: Response rate|Survival|Toxicity Sponsors and Collaborators: European Lung Cancer Working Party Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00634205...

Continue reading

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 30 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000066141|P30CA016087|NYU-9850|MDA-FDR001234|MDA-ID-95209|NCI-G99-1575 Study First Received: December 10, 1999 Last Updated: March 25, 2011 Estimated Primary Completion Date: May 2001 Primary Outcome Measures: Sponsors and Collaborators: New York University School of Medicine|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004033...

Continue reading

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 77 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: ONC-2006-003|EUDRACT 2006-004429-27 Study First Received: December 4, 2006 Last Updated: August 31, 2011 Estimated Primary Completion Date: November 2010 Primary Outcome Measures: Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive.|Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma.|Overall survival (OS) computed as the time between the...

Continue reading

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Condition Advanced Malignant Mesothelioma|Recurrent Malignant Mesothelioma Estimated Enrollment: 39 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2009-00693|CDR0000652058|NCIC-183 Study First Received: October 25, 2006 Last Updated: May 5, 2014 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Objective Response (Partial and Complete) Per RECIST Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: October 21, 2013 Website Link: https://ClinicalTrials.gov/show/NCT00392444...

Continue reading